CVM:NYSEAMERICAN
CEL-SCI Corp
၁.၆၉ US$
arrow_downward
-၂၅.၈၈%(-၀.၅၉) 1D
၁.၆၉ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: မေ ၄, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CVM...
Open
၂.၁၆ US$
High
၂.၁၆ US$
Low
၁.၅၇ US$
Mkt. cap
၁.၄၃ ကုဋေ
Avg. vol.
၈.၆၆ သောင်း
Volume
၀.၀၀
52-wk high
၁၃.၄၈ US$
52-wk low
၁.၅၇ US$
EPS
-၅.၂၄ US$
Beta
၀.၇၀
Shares outstanding
၈.၄၆ သန်း
No. of employees
၄၃
News stories
From sources across the web
Stock Titan
·
ပြီးခဲ့သည့် ၃ ရက်
CEL-SCI (NYSE: CVM) moves to fund Multikine with $13.7M best efforts stock sale
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees၄၃
Foundedမတ် ၁၉၈၃
Headquartersဗီယင်နာ, ဗာဂျီးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitecel-sci.com
AI content may include mistakes. Learn more